trending Market Intelligence /marketintelligence/en/news-insights/trending/WRgKhyhRPBTM1Mwpalqe1w2 content esgSubNav
In This List

Fennec Pharmaceuticals closes $7.6M private placement of common shares

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


Fennec Pharmaceuticals closes $7.6M private placement of common shares

Fennec Pharmaceuticals Inc. completed a nonbrokered private placement of 1.9 million common shares, priced $4.00 apiece, for gross proceeds of $7.6 million.

The placement was led by venBio Select Advisor LLC and included existing and new investors.

The company plans to use net proceeds for the development of sodium thiosulfate, or STS, and for general working capital purposes. The company is studying potential benefits of STS in pediatric cancer patients.

In connection with the placement, Essetifin SpA bought an additional 300,000 shares, increasing its stake in Fennec to 2,931,579 shares.

Prior to the offering, the company had 13,707,306 outstanding shares.

The shares issued are subject to a hold period, which will expire four months plus one day from the closing date.